In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors

Pesini, Cecilia ; Artal, Laura ; Paúl Bernal, Jorge ; Sánchez Martinez, Diego ; Pardo, Julián (Universidad de Zaragoza) ; Ramírez-Labrada, Ariel

Resumen: Natural killer (NK) cells play a crucial role in antitumoral and antiviral responses. Yet, cancer cells can alter themselves or the microenvironment through the secretion of cytokines or other factors, hindering NK cell activation and promoting a less cytotoxic phenotype. These resistance mechanisms, often referred to as the “hallmarks of cancer” are significantly influenced by the activation of oncogenes, impacting most, if not all, of the described hallmarks. Along with oncogenes, other types of genes, the tumor suppressor genes are frequently mutated or modified during cancer. Traditionally, these genes have been associated with uncontrollable tumor growth and apoptosis resistance. Recent evidence suggests oncogenic mutations extend beyond modulating cell death/proliferation programs, influencing cancer immunosurveillance. While T cells have been more studied, the results obtained highlight NK cells as emerging key protagonists for enhancing tumor cell elimination by modulating oncogenic activity. A few recent studies highlight the crucial role of oncogenic mutations in NK cell-mediated cancer recognition, impacting angiogenesis, stress ligands, and signaling balance within the tumor microenvironment. This review will critically examine recent discoveries correlating oncogenic mutations to NK cell-mediated cancer immunosurveillance, a relatively underexplored area, particularly in the era dominated by immune checkpoint inhibitors and CAR-T cells. Building on these insights, we will explore opportunities to improve NK cell-based immunotherapies, which are increasingly recognized as promising alternatives for treating low-antigenic tumors, offering significant advantages in terms of safety and manufacturing suitability.

Idioma: Inglés

DOI: 10.1080/2162402X.2024.2379062

Año: 2024

Publicado en: OncoImmunology 13, 1 (2024), [22 pp.]
ISSN: 2162-4011

Factor impacto JCR: 6.3 (2024)

Categ. JCR: ONCOLOGY rank: 51 / 326 = 0.156 (2024) - Q1 - T1
Categ. JCR: IMMUNOLOGY rank: 31 / 183 = 0.169 (2024) - Q1 - T1

Factor impacto SCIMAGO: 2.542 - Immunology (Q1) - Oncology (Q1) - Immunology and Allergy (Q1)

Financiación: info:eu-repo/grantAgreement/ES/AEI/PID2020-113963RB-I00
Financiación: info:eu-repo/grantAgreement/ES/AEI/RYC2022-036627-I
Financiación: info:eu-repo/grantAgreement/ES/DGA/B29-23R
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/CB21-13-00087
Financiación: info:eu-repo/grantAgreement/ES/MICINN/PID2022-136554OA-I00

Tipo y forma: Revisión (Versión definitiva)

Área (Departamento): Área Inmunología (Dpto. Microb.Ped.Radio.Sal.Pú.)